Sartorius Aktiengesellschaft

Research Sartorius Aktiengesellschaft (SRT3) on Bullrun: market cap EUR 17.84B, P/E 91.3, dividend yield 0.3%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 17.84B; P/E is 91.3; dividend yield is 0.3%.

Peer valuation comparison

Latest P/E is 91.27x versus a Healthcare sector median of 24.6x (271.0% above).

Latest dividend yield is 0.29% versus a Healthcare sector median of 1.84% (84.2% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 3.54BEUR 218.00Mn/a46.3%n/aEUR 541.40MEUR 4.28BEUR 2.71B
FY2024EUR 3.38BEUR 119.40Mn/a45.1%n/aEUR 813.40MEUR 4.56BEUR 2.76B
FY2023EUR 3.40BEUR 205.50Mn/a46.2%n/aEUR 379.20Mn/an/a
FY2022EUR 4.18BEUR 678.10Mn/a52.2%n/aEUR 165.90Mn/an/a

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-09-27EUR 17.84B91.30.3%0.74

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.74 EUR, yield 0.3%.

About Sartorius Aktiengesellschaft

Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Sartorius Aktiengesellschaft's market cap?

Sartorius Aktiengesellschaft's market capitalization is EUR 17.84B.

What is Sartorius Aktiengesellschaft's P/E ratio?

Sartorius Aktiengesellschaft's price-to-earnings (P/E) ratio is 91.3.

Does Sartorius Aktiengesellschaft pay a dividend?

Sartorius Aktiengesellschaft has a dividend yield of 0.3%.

What does Sartorius Aktiengesellschaft do?

Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid.